BHC vs. APHA, PBH, AUP, CARA, TLRY, CRON, TEV, SLS, ABT, and NOT
Should you be buying Bausch Health Companies stock or one of its competitors? The main competitors of Bausch Health Companies include Aphria (APHA), Premium Brands (PBH), Aurinia Pharmaceuticals (AUP), Cara Operations (CARA), Tilray Brands (TLRY), Cronos Group (CRON), Tervita (TEV), Solaris Resources (SLS), Absolute Software Co. (ABT.TO) (ABT), and Noront Resources (NOT). These companies are all part of the "pharmaceutical products" industry.
Bausch Health Companies vs.
Bausch Health Companies (TSE:BHC) and Aphria (TSE:APHA) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, community ranking, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.
79.0% of Bausch Health Companies shares are owned by institutional investors. 11.3% of Bausch Health Companies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Bausch Health Companies has higher revenue and earnings than Aphria. Bausch Health Companies is trading at a lower price-to-earnings ratio than Aphria, indicating that it is currently the more affordable of the two stocks.
In the previous week, Bausch Health Companies had 5 more articles in the media than Aphria. MarketBeat recorded 5 mentions for Bausch Health Companies and 0 mentions for Aphria. Aphria's average media sentiment score of 0.00 beat Bausch Health Companies' score of -0.09 indicating that Aphria is being referred to more favorably in the news media.
Aphria received 342 more outperform votes than Bausch Health Companies when rated by MarketBeat users. Likewise, 68.04% of users gave Aphria an outperform vote while only 63.93% of users gave Bausch Health Companies an outperform vote.
Aphria has a net margin of 0.00% compared to Bausch Health Companies' net margin of -1.88%. Bausch Health Companies' return on equity of 15.87% beat Aphria's return on equity.
Bausch Health Companies presently has a consensus target price of C$9.00, suggesting a potential downside of 13.54%. Given Aphria's higher probable upside, analysts plainly believe Aphria is more favorable than Bausch Health Companies.
Summary
Bausch Health Companies beats Aphria on 9 of the 15 factors compared between the two stocks.
Get Bausch Health Companies News Delivered to You Automatically
Sign up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bausch Health Companies Competitors List
Related Companies and Tools
This page (TSE:BHC) was last updated on 2/22/2025 by MarketBeat.com Staff
